Literature DB >> 25827742

Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.

C Feliciani1, P Joly, M F Jonkman, G Zambruno, D Zillikens, D Ioannides, C Kowalewski, H Jedlickova, S Kárpáti, B Marinovic, D Mimouni, S Uzun, S Yayli, M Hertl, L Borradori.   

Abstract

Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients, bullae may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. Our consensus for the treatment of bullous pemphigoid has been developed under the guidance of the European Dermatology Forum in collaboration with the European Academy of Dermatology and Venereology. It summarizes evidence-based and expert-based recommendations.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25827742     DOI: 10.1111/bjd.13717

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  58 in total

1.  Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid.

Authors:  Joost M Meijer; Gilles F H Diercks; Emma W G de Lang; Hendri H Pas; Marcel F Jonkman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

3.  A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis.

Authors:  Marco Folci; Giacomo Ramponi; Enrico Brunetta
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature.

Authors:  Meital Oren-Shabtai; Noa Kremer; Moshe Lapidoth; Eran Sharon; Lihi Atzmony; Adi Nosrati; Emmilia Hodak; Daniel Mimouni; Assi Levi
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

Review 5.  Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Authors:  Susanne Radonjic-Hoesli; Kathrin Scherer Hofmeier; Sara Micaletto; Peter Schmid-Grendelmeier; Andreas Bircher; Dagmar Simon
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

6.  Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient.

Authors:  Francisco J Navarro-Triviño; Jose Maria Llamas-Molina; Angela Ayen-Rodriguez; Barbara Cancela-Díez; Ricardo Ruiz-Villaverde
Journal:  Eur J Hosp Pharm       Date:  2020-09-12

7.  Efficacy and safety of tetracyclines for pemphigoid: a systematic review and meta-analysis.

Authors:  Xin-Xing Jin; Xue Wang; Ying Shan; Si-Zhe Li; Qun Xu; Hong-Zhong Jin; Ya-Gang Zuo
Journal:  Arch Dermatol Res       Date:  2021-03-28       Impact factor: 3.017

Review 8.  Alopecia in Autoimmune Blistering Diseases: A Systematic Review of Pathogenesis and Clinical Features of Disease.

Authors:  Danica Xie; Asli Bilgic-Temel; Nada Abu Alrub; Dédée F Murrell
Journal:  Skin Appendage Disord       Date:  2019-07-10

9.  Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.

Authors:  Xiuting Liu; Jianchi Ma; Xiaonan Qiu; Dan Hong; Liangchun Wang; Zhenrui Shi
Journal:  Eur J Dermatol       Date:  2021-12-01       Impact factor: 3.328

10.  A Late Dermatologic Presentation of Bullous Pemphigoid Induced by Anti-PD-1 Therapy and Associated with Unexplained Neurological Disorder.

Authors:  Xiaoxiao Wang; Mariano Suppa; Pascal Bruderer; Nicolas Sirtaine; Sandrine Aspeslagh; Joseph Kerger
Journal:  Case Rep Oncol       Date:  2021-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.